Loading...
•
Jun 30, 2020
Abeona Therapeutics Q2 2020 Earnings Report
Announced financial results for the second quarter 2020 and recent business progress.
Key Takeaways
Abeona Therapeutics reported its Q2 2020 financial results, highlighting progress in clinical development, manufacturing, and regulatory affairs. New patients were treated in RDEB and MPS IIIA clinical programs, and internal manufacturing operations resumed in June. General alignment was reached with the CHMP on the path for European marketing authorization application for ABO-102 in MPS IIIA.
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs
General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA
Data from RDEB and MPS III programs presented at recent medical meetings
Strengthened leadership team with appointment of experienced Chief Commercial Officer and two independent Board members
Abeona Therapeutics
Abeona Therapeutics
Forward Guidance
Abeona expects additional patient enrollment across its clinical programs and anticipates starting internal manufacturing of retrovirus and AAV in late-2020 and early-2021, respectively. The company anticipates a European marketing authorization application for ABO-102 in MPS IIIA in 2023 and potential commercial launches of EB-101 in late-2022 and ABO-102 the following year.